CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19CAR-T 细胞治疗后白血病复发的遗传机制
英文原题：Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.
查看英文原题
Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法（CAR-T）在过去10年中治疗白血病取得了良好的效果。抗CD19 CAR-T 治疗B细胞急性淋巴细胞白血病可达到90%的完全缓解率。尽管CAR-T 极大地改善了白血病和淋巴瘤患者的治疗，但多达三分之一的患者可能在CAR-T 后出现疾病复发。大多数复发患者的肿瘤表面标志物CD19为阴性，而这些患者在治疗前CD19高表达。本综述简要总结了抗白血病CD19 CAR-T 后CD19阴性复发的当前原因及靶点逃逸机制。同时，还讨论了治疗复发的方法和策略，为白血病复发的治疗提供参考。
展开英文摘要原文
Chimeric antigen receptor T cell therapy (CART) has achieved excellent results in the past 10 years for treating of leukemia. Treatment of B cell acute lymphoblastic leukemia by anti-CD19 CART can reach a complete remission rate of 90%. Although CART has greatly improved the treatment of patients with leukemia and lymphoma, as many as one-third of the patients can suffer disease relapse after CART.
The tumor surface marker CD19 is negative in most the patients who relapse, and these patients display high expression of CD19 before treatment. In this review, the current causes of CD19-negative relapses after CD19 CART against leukemia, and the mechanisms of target escape are briefly summarized. Also, methods and strategies for treating relapse to provide references for the treatment of leukemia relapse are also discussed.
论文信息
- 作者
- Qiu S、Pan Y、Shi S、Omotoyosi FF、Chen K、Guo Z、Lü P
- 单位
- School of Life Sciences, Jiangsu University, Zhenjiang, China.China
- 文献类型
- 综述
- 期刊
- Cancer biotherapy & radiopharmaceuticals2022 Jun
- 原文标识
- PubMed 33739864 · DOI 10.1089/cbr.2020.4630